Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 9 studies | 32% ± 14% | |
| type II pneumocyte | 9 studies | 34% ± 13% | |
| hepatocyte | 4 studies | 69% ± 15% | |
| mesothelial cell | 3 studies | 19% ± 3% | |
| endothelial cell | 3 studies | 22% ± 3% | |
| astrocyte | 3 studies | 21% ± 3% |
Insufficient scRNA-seq data for expression of HSD17B6 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 97% | 1879.76 | 237 / 245 | 97% | 106.66 | 485 / 502 |
| liver | 100% | 24204.15 | 226 / 226 | 91% | 442.19 | 369 / 406 |
| brain | 99% | 934.45 | 2605 / 2642 | 79% | 14.41 | 560 / 705 |
| thymus | 95% | 1116.76 | 622 / 653 | 71% | 41.44 | 431 / 605 |
| lung | 94% | 1380.03 | 545 / 578 | 63% | 18.65 | 728 / 1155 |
| uterus | 95% | 1271.29 | 162 / 170 | 49% | 9.02 | 226 / 459 |
| bladder | 100% | 2756.81 | 21 / 21 | 38% | 5.46 | 191 / 504 |
| intestine | 92% | 975.51 | 891 / 966 | 17% | 2.33 | 91 / 527 |
| spleen | 100% | 2805.21 | 241 / 241 | 0% | 0 | 0 / 0 |
| stomach | 75% | 281.40 | 270 / 359 | 17% | 1.32 | 50 / 286 |
| ovary | 69% | 301.48 | 125 / 180 | 12% | 0.98 | 50 / 430 |
| breast | 3% | 17.10 | 16 / 459 | 69% | 7.95 | 776 / 1118 |
| blood vessel | 53% | 444.60 | 713 / 1335 | 0% | 0 | 0 / 0 |
| esophagus | 24% | 77.42 | 347 / 1445 | 28% | 2.35 | 52 / 183 |
| adipose | 45% | 346.83 | 539 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 0% | 0 | 0 / 328 | 39% | 4.12 | 70 / 178 |
| adrenal gland | 24% | 64.03 | 63 / 258 | 11% | 11.30 | 26 / 230 |
| tonsil | 0% | 0 | 0 / 0 | 29% | 2.13 | 13 / 45 |
| kidney | 18% | 56.55 | 16 / 89 | 3% | 0.98 | 29 / 901 |
| skin | 6% | 19.82 | 106 / 1809 | 4% | 0.36 | 20 / 472 |
| heart | 3% | 11.69 | 26 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 2% | 9.52 | 19 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.12 | 1 / 80 |
| muscle | 1% | 1.32 | 5 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006710 | Biological process | androgen catabolic process |
| GO_0062175 | Biological process | brexanolone catabolic process |
| GO_0008202 | Biological process | steroid metabolic process |
| GO_0006702 | Biological process | androgen biosynthetic process |
| GO_0042572 | Biological process | retinol metabolic process |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0031901 | Cellular component | early endosome membrane |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
| GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
| GO_0004745 | Molecular function | all-trans-retinol dehydrogenase (NAD+) activity |
| GO_0016491 | Molecular function | oxidoreductase activity |
| GO_0047024 | Molecular function | 5alpha-androstane-3beta,17beta-diol dehydrogenase activity |
| GO_0003824 | Molecular function | catalytic activity |
| GO_0047035 | Molecular function | testosterone dehydrogenase (NAD+) activity |
| GO_0047044 | Molecular function | androstan-3-alpha,17-beta-diol dehydrogenase activity |
| GO_0047023 | Molecular function | androsterone dehydrogenase activity |
| GO_0009055 | Molecular function | electron transfer activity |
| Gene name | HSD17B6 |
| Protein name | Hydroxysteroid 17-beta dehydrogenase 6 17-beta-hydroxysteroid dehydrogenase type 6 (17-beta-HSD 6) (17-beta-HSD6) (EC 1.1.1.105) (EC 1.1.1.209) (EC 1.1.1.239) (EC 1.1.1.53) (EC 1.1.1.62) (3-alpha->beta-hydroxysteroid epimerase) (3-alpha->beta-HSE) (Oxidative 3-alpha hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 9C member 6) 17-beta-hydroxysteroid dehydrogenase type 6 variant 2 17-beta-hydroxysteroid dehydrogenase type 6 variant 3 17-beta-hydroxysteroid dehydrogenase type 6 variant 1 |
| Synonyms | SDR9C6 RODH |
| Description | FUNCTION: NAD-dependent oxidoreductase with broad substrate specificity that shows both oxidative and reductive activity (in vitro). Has 17-beta-hydroxysteroid dehydrogenase activity towards various steroids (in vitro). Converts 5-alpha-androstan-3-alpha,17-beta-diol to androsterone and estradiol to estrone (in vitro). Has 3-alpha-hydroxysteroid dehydrogenase activity towards androsterone (in vitro). Has retinol dehydrogenase activity towards all-trans-retinol (in vitro). Can convert androsterone to epi-androsterone. Androsterone is first oxidized to 5-alpha-androstane-3,17-dione and then reduced to epi-andosterone. Can act on both C-19 and C-21 3-alpha-hydroxysteroids. . |
| Accessions | ENST00000322165.1 ENST00000555159.5 ENST00000554643.5 ENST00000555805.5 G3V508 ENST00000554155.1 ENST00000556650.5 ENST00000554150.5 A0A219K684 G3V3Y9 O14756 A0A219K5H4 A0A219KCD5 |
